Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 291-294, 2022.
Article
en Zh
| WPRIM
| ID: wpr-928811
Biblioteca responsable:
WPRO
ABSTRACT
Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Traumatismos por Radiación
/
Encéfalo
/
Inhibidores de la Angiogénesis
/
Consenso
/
Factor A de Crecimiento Endotelial Vascular
/
Bevacizumab
/
Neoplasias Pulmonares
/
Necrosis
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Article